No Data
Arbutus Biopharma Reshapes Strategy After Moderna Settlement
Arbutus Biopharma Shares Are Trading Higher After the Company Announced the Filing of Three International Lawsuits Seeking to Enforce Patent Protecting LNP Technology Against Pfizer, BioNTech and Certain or Other Affiliates.
Arbutus Biopharma Announces Filing Of Three International Lawsuits Seeking To Enforce Patents Protecting LNP Technology Against Pfizer, BioNTech And Certain Of Their Affiliates
Express News | Arbutus Biopharma Corp - Anticipates Receipt of Dividend From Genevant in Q3 2026
Express News | Arbutus Biopharma Corp - Expects to Return up to $230 Mln in Capital to Shareholders
Express News | Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders